The transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) is characterized by an increasing neurodegenerative component. Identifying biomarkers that distinguish these disease stages is crucial for early diagnosis and treatment optimization. This study aimed to compare serum levels of progranulin, interleukin-6 (IL-6), semaphorin 3A (SEMA3A), and neurofilaments between RRMS and SPMS patients and to investigate their correlation with clinical characteristics, including disability measured by the Expanded Disability Status Scale (EDSS). This observational study included 118 MS patients (63 RRMS and 55 SPMS). Serum biomarker levels were measured using an enzyme-linked immunosorbent assay (ELISA). Statistical analyses included group comparisons using non-parametric tests and correlation analyses using Pearson's correlation coefficient with multiple testing corrections. While demographic and clinical parameters significantly differed between groups (p < 0.001), biomarker levels showed no statistically significant differences (p > 0.05). However, in SPMS patients, SEMA3A correlated positively with neurofilaments (r = 0.359, p = 0.007), and progranulin correlated with IL-6 (r = 0.354, p = 0.008). No significant biomarker correlations with EDSS were found. Although absolute biomarker levels did not distinguish RRMS from SPMS, specific biomarker correlations may reflect processes relevant to disease progression and warrant further longitudinal validation.

Department of Clinical Immunology and Allergology University Hospital Hradec Králové 50005 Hradec Králové Czech Republic

Department of Neurology Faculty of Medicine in Hradec Králové Charles University 50005 Hradec Králové Czech Republic

Department of Neurology University Hospital Hradec Králové 50005 Hradec Králové Czech Republic

Novartis s r o 14000 Prague Czech Republic

Zobrazit více v PubMed

Cree B.A.C., Arnold D.L., Chataway J., Chitnis T., Fox R.J., Ramajo A.P., Murphy N., Lassmann H. Secondary Progressive Multiple Sclerosis: New Insights. Neurology. 2021;97:378–388. doi: 10.1212/WNL.0000000000012323. PubMed DOI PMC

Gill A.J., Schorr E.M., Gadani S.P., Calabresi P.A. Emerging Imaging and Liquid Biomarkers in Multiple Sclerosis. Eur. J. Immunol. 2023;53:e2250228. doi: 10.1002/eji.202250228. PubMed DOI PMC

Chitnis T., Qureshi F., Gehman V.M., Becich M., Bove R., Cree B.A.C., Gomez R., Hauser S.L., Henry R.G., Katrib A., et al. Inflammatory and Neurodegenerative Serum Protein Biomarkers Increase Sensitivity to Detect Clinical and Radiographic Disease Activity in Multiple Sclerosis. Nat. Commun. 2024;15:4297. doi: 10.1038/s41467-024-48602-9. PubMed DOI PMC

Podbielska M., O’Keeffe J., Pokryszko-Dragan A. New Insights into Multiple Sclerosis Mechanisms: Lipids on the Track to Control Inflammation and Neurodegeneration. Int. J. Mol. Sci. 2021;22:7319. doi: 10.3390/ijms22147319. PubMed DOI PMC

Agnello L., Gambino C.M., Ciaccio A.M., Masucci A., Vassallo R., Tamburello M., Scazzone C., Lo Sasso B., Ciaccio M. Molecular Biomarkers of Neurodegenerative Disorders: A Practical Guide to Their Appropriate Use and Interpretation in Clinical Practice. Int. J. Mol. Sci. 2024;25:4323. doi: 10.3390/ijms25084323. PubMed DOI PMC

Srpova B., Uher T., Hrnciarova T., Barro C., Andelova M., Michalak Z., Vaneckova M., Krasensky J., Noskova L., Havrdova E.K., et al. Serum Neurofilament Light Chain Reflects Inflammation-Driven Neurodegeneration and Predicts Delayed Brain Volume Loss in Early Stage of Multiple Sclerosis. Mult. Scler. J. 2021;27:52–60. doi: 10.1177/1352458519901272. PubMed DOI

Good P.F., Alapat D., Hsu A., Chu C., Perl D., Wen X., Burstein D.E., Kohtz D.S. A Role for Semaphorin 3A Signaling in the Degeneration of Hippocampal Neurons during Alzheimer’s Disease. J. Neurochem. 2004;91:716–736. doi: 10.1111/j.1471-4159.2004.02766.x. PubMed DOI

Tanaka T., Narazaki M., Kishimoto T. IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harb. Perspect. Biol. 2014;6:a016295. doi: 10.1101/cshperspect.a016295. PubMed DOI PMC

Kerkis I., da Silva Á.P., Araldi R.P. The Impact of Interleukin-6 (IL-6) and Mesenchymal Stem Cell-Derived IL-6 on Neurological Conditions. Front. Immunol. 2024;15:1400533. doi: 10.3389/fimmu.2024.1400533. PubMed DOI PMC

Zhang W., Xiao D., Mao Q., Xia H. Role of Neuroinflammation in Neurodegeneration Development. Signal Transduct. Target. Ther. 2023;8:267. doi: 10.1038/s41392-023-01486-5. PubMed DOI PMC

Mendsaikhan A., Tooyama I., Walker D.G. Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases. Cells. 2019;8:230. doi: 10.3390/cells8030230. PubMed DOI PMC

Ziemssen T., Smolinski L., Członkowska A., Akgun K., Antos A., Bembenek J., Kurkowska-Jastrzębska I., Przybyłkowski A., Skowrońska M., Redzia-Ogrodnik B., et al. Serum Neurofilament Light Chain and Initial Severity of Neurological Disease Predict the Early Neurological Deterioration in Wilson’s Disease. Acta Neurol. Belg. 2023;123:917–925. doi: 10.1007/s13760-022-02091-z. PubMed DOI PMC

Ziemssen T., Arnold D.L., Alvarez E., Cross A.H., Willi R., Li B., Kukkaro P., Kropshofer H., Ramanathan K., Merschhemke M., et al. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Front. Immunol. 2022;13:852563. doi: 10.3389/fimmu.2022.852563. PubMed DOI PMC

Thompson A.J., Banwell B.L., Barkhof F., Carroll W.M., Coetzee T., Comi G., Correale J., Fazekas F., Filippi M., Freedman M.S., et al. Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria. Lancet Neurol. 2018;17:162–173. doi: 10.1016/S1474-4422(17)30470-2. PubMed DOI

Lublin F.D., Reingold S.C., National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis Defining the Clinical Course of Multiple Sclerosis: Results of an International Survey. Neurology. 1996;46:907–911. doi: 10.1212/WNL.46.4.907. PubMed DOI

Lublin F.D., Reingold S.C., Cohen J.A., Cutter G.R., Sørensen P.S., Thompson A.J., Wolinsky J.S., Balcer L.J., Banwell B., Barkhof F., et al. Defining the Clinical Course of Multiple Sclerosis: The 2013 Revisions. Neurology. 2014;83:278–286. doi: 10.1212/WNL.0000000000000560. PubMed DOI PMC